LEUPRORELIN

Information current as at: 1 June 2026

The processes outlined in the MSW are not applicable to this medicine. Please contact pbs@health.gov.au or 1800 020 613 for further information.

Legend:

Completed N In progress

Not applicable N Yet to commence

Submission Details

Brand name:: Eligard®
Form and strength:: Please search for and view the medicine's Public Summary Document (PSD) for more information
Submission sponsor:: MUNDIPHARMA PTY LIMITED
Condition/indication: (therapeutic use): Central precocious puberty Locally advanced (stage C) or metastatic (stage D) carcinoma of the prostate
Listing requested:: Please see PSD for more information
Funding program:: Please see PSD for more information
Request authority level:: Please see PSD for more information
PBAC Submission type:: Change to existing listing (Committee Secretariat)
Comment:: --
Other PBAC consideration:: --

Submission received for:: November 2024 PBAC meeting
Opportunity for consumer comment:: Open 31/07/2024 and close 25/09/2024 (see PBS Website)
PBAC meeting:: Held on 06/11/2024
PBAC outcome published:: Recommended (see PBAC Outcomes)
Notice of intent submitted:: Not Applicable
Lodgement of required documentation:: Not applicable
Agreement to listing arrangements:: Not applicable
Government processes:: Not applicable
Medicine listed on the PBS:: Not applicable

PBAC Recommendation:

Please see the Outcomes from the relevant meeting for more information

Public Summary Document:

Case ID

a946

Page last updated

31 March 2026

v.9.19